Page 2 of 2

Posted: Fri Jan 29, 2010 9:32 am
by ozarkcanoer
hmmmmm... If I have a big pharma company paying for MY research isn't this also kind of like a wealthy frient ?

ozarkcanoer

Posted: Sat Jan 30, 2010 10:44 am
by kjwxau
As to what Dr Munsch ment by" wealthy" I couldn't inturrpert his meaning. I took it as negative originally but then I mulled it over and though I was just being sensitive.
My friend from Chicago went to Mayo and took the info to her Dr who is a Devic's specialist and she did not get a good reception when she asked about the ccsvi. In fact she was downright negative and dismissed the Jacobs/UB study as not being run correctly. I did get to mention that to Dr. Gutt-Weinst and she asked me her name. She named a Dr and I was prettty sure that was her. I had so many things I wanted to ask her but I was not in for a appt with her specifically.
I forgot to add tha she did mention a Dr who I think I might have a link to for the surgical correction. In the small world of Bufffalo his son plays hockey against mine. Last night I ran into his coach that my husband went to school with at the Buffalo sabres game. I briefly asked about the Dr and ask if he was approchable. He said email your questions and I'll ask him, he is very approchable . Interstingly enough he is a neurosurgeon but went on went on the UB web sight he also is a radiologist and two other listing. If anybody has a good list of questions I could ask please PM me.

Posted: Fri Feb 05, 2010 4:57 pm
by bestadmom
Re Zamboni's funding, there was none from a wealthy Italian man. He did hs research on a shoestring according to someone I know who is very close with him and very involved in MS and CCSVI research.

Posted: Fri Feb 05, 2010 5:35 pm
by Billmeik
if ccsvi is true will there be another round of drugs for MS? Maybe legacy MS patients need symptom relief but others in early stages shouldn't progress and should sort of be 'cured' of the disease

Posted: Fri Feb 05, 2010 5:35 pm
by Billmeik
if ccsvi is true will there be another round of drugs for MS? Maybe legacy MS patients need symptom relief but others in early stages shouldn't progress and should sort of be 'cured' of the disease

Posted: Sat Feb 06, 2010 9:22 pm
by catfreak
I have to agree with Cheer none of this is a coincidence. This is the Dr that downed CCSVI at a conference in FL last weekend and now he is with Biogen?????

Cat

Dr. Juurlink and Dr.Munschauer had something in common

Posted: Mon Aug 30, 2010 5:58 am
by KDGO
I know this is water under the bridge but these 2 excerpts show something interesting.

Start MS trials now, says ex-U of S prof

Researcher proposed bloodflow theory in 1998

BY HANNAH SCISSONS, THE STARPHOENIXAUGUST 28, 2010

Bernhard Juurlink published a hypothesis in 1998 -- while he was a scientist at the Cameco MS Neuroscience Research Centre in Saskatoon -- that MS is related to decreased bloodflow in the brain and spinal cord.
"It was very difficult to get anyone interested in this idea -- the idea was easily testable by, for example, looking for bloodflow in white matter in MS patients," Juurlink said in an interview with The StarPhoenix this week. "I tried to first interest clinical colleagues to image brains of MS and non-MS patients, to look at bloodflow, with no success."
He said his research into strokes intersected with MS research during the 1990s when he started looking at the development of the cells that form myelin, the fatty sheaths around the axons of the brain. Damage to the myelin sheaths caused by immune cell attacks is the commonly accepted cause of MS.


Article: Munschauer is leaving neurological institute
Article from:Buffalo News Article date:January 27, 2010 Author:Henry L. Davis
The chief of the Jacobs Neurological Institute in Buffalo is leaving to become vice president of U.S. medical affairs for Biogen Idec, a pharmaceutical company best known for its multiple sclerosis therapies.
Dr. Frederick Munschauer III, an authority on multiple sclerosis and such vascular diseases as stroke, also is chairman of the University at Buffalo Department of Neurology.